Zhu Qianhong, Luo Qiuyi, Wang Zhichen, Chen Senlin, Chen Gengzhao, Huang Saie
Fujian University of Traditional Chinese Medicine Subsidiary Rehabilitation Hospital, Fuzhou, China.
Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Sleep Breath. 2025 May 9;29(2):182. doi: 10.1007/s11325-025-03348-6.
In this meta-analysis, we provide the findings of randomized controlled trials on the levels of inflammatory markers in patients with obstructive sleep apnea (OSA) receiving continuous positive airway pressure (CPAP).
Literature published in the PubMed, Web of Science, Embase and Cochrane databases up to May 21, 2024, was comprehensively searched, and inclusion and exclusion criteria were developed. Pooled estimates of CPAP therapy were analyzed via the standardized mean difference (SMD). This meta-analysis follows the PRISMA 2020 guidelines and is registered with PROSPERO (ID CRD42024548588).
A total of 15 studies were included, each reporting data on one or more inflammatory markers, as follows: 10 studies on C-reactive protein (CRP), 12 studies on interleukin-6 (IL-6), 3 studies on interleukin-8 (IL-8), and 9 studies on tumor necrosis factor-α (TNF-α). The results revealed that the SMDs (95% confidence intervals [CIs]) for CRP, IL-6, IL-8 and TNF-α levels before and after CPAP treatment were 0.88 (95% CI 0.28-1.48), 0.58 (95% CI 0.12-1.05), 0.20 (95% CI 0.39-0.80) and 0.17 (95% CI 0.05-0.29), separately.
CPAP therapy used for a certain duration can lower CRP, IL-6 and TNF-α levels in OSA patients, and there are substantial differences observed in the various inflammatory indicators. To confirm the usefulness of these biomarkers in evaluating CPAP therapy for cardiovascular risk reduction among OSA patients, more randomized controlled trials (RCTs) have to be carried out in the future.
在这项荟萃分析中，我们呈现了关于阻塞性睡眠呼吸暂停（OSA）患者接受持续气道正压通气（CPAP）治疗时炎症标志物水平的随机对照试验结果。
全面检索了截至2024年5月21日在PubMed、科学网、Embase和Cochrane数据库中发表的文献，并制定了纳入和排除标准。通过标准化均值差（SMD）分析CPAP治疗的合并估计值。本荟萃分析遵循PRISMA 2020指南，并在PROSPERO（ID CRD42024548588）注册。
共纳入15项研究，每项研究报告了一种或多种炎症标志物的数据，具体如下：10项关于C反应蛋白（CRP）的研究，12项关于白细胞介素-6（IL-6）的研究，3项关于白细胞介素-8（IL-8）的研究，以及9项关于肿瘤坏死因子-α（TNF-α）的研究。结果显示，CPAP治疗前后CRP、IL-6、IL-8和TNF-α水平的SMD（95%置信区间[CI]）分别为0.88（95%CI 0.28 - 1.48）、0.58（95%CI 0.12 - 1.05）、0.20（95%CI 0.39 - 0.80）和0.17（95%CI 0.05 - 0.29）。
持续一定时间的CPAP治疗可降低OSA患者的CRP、IL-6和TNF-α水平，且各炎症指标存在显著差异。为证实这些生物标志物在评估CPAP治疗对降低OSA患者心血管风险的有效性，未来还需开展更多随机对照试验（RCT）。
